However, few previous studies have evaluated the impacts of socioeconomic deprivation on outcomes from treatment with erlotinib, gefitinib, or other systemic anticancer therapies in patients with EGFR-mutant or other forms of advanced lung cancer. This evidence concerns the gene EGFR and lung cancer.